Back to Search
Start Over
Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a 'real-world' chart review study
- Source :
- Brazilian Journal of Psychiatry, Vol 42, Iss 3, Pp 317-321, Brazilian Journal of Psychiatry, Volume: 42, Issue: 3, Pages: 317-321, Published: 09 MAR 2020, Brazilian Journal of Psychiatry, Brazilian Journal of Psychiatry, Issue: ahead, Published: 09 MAR 2020
- Publication Year :
- 2020
-
Abstract
- Objective: Selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of treatment of major depressive disorder (MDD). However, non-response is common, often necessitating combination strategies. The present study assessed the efficacy of vortioxetine as an add-on therapy in patients with SSRI-resistant MDD. Methods: The charts of 36 adult outpatients with DSM-IV-TR MDD who had not achieved a response after at least 8 weeks of treatment with an SSRI were reviewed retrospectively. Subjects were treated with vortioxetine (5-20 mg/day) for 8 weeks added to the current SSRI. The main outcome measures were change from baseline in total Hamilton Scale for Depression (HAM-D) score and the rate of response (a 50% or greater reduction in HAM-D score and a Clinical Global Impression ‐ Improvement module [CGI-I] score of 1 or 2 at endpoint). HAM-D scores ≤ 7 were considered as remission. Additional outcome measures included the Snaith-Hamilton Pleasure Scale (SHAPS) and the Scale for Suicide Ideation (SSI). Results: 32 patients completed the 8 weeks of treatment. At 8 weeks, a significant reduction in HAM-D score was observed (p ≤ 0.001), with response obtained by 41.7% and remission by 33.3% of patients. Significant reductions in SHAPS and SSI were also observed (p ≤ 0.001 for both scales). Conclusions: Adjunctive vortioxetine may be useful and well-tolerated in stage I treatment-resistant depression. However, the limitations of this study (such as small sample size, absence of randomization and control group, retrospective design, etc.) must be considered.
- Subjects :
- Male
PHARMACOKINETICS
Time Factors
SSRI-resistant major depressive disorder
Depressive Disorder, Treatment-Resistant
0302 clinical medicine
lcsh:Psychiatry
Serotonin and Noradrenaline Reuptake Inhibitors
Depression (differential diagnoses)
real world
ssri-resistant major depressive disorder
ANTIDEPRESSANTS
Antidepressive Agents
Psychiatry and Mental health
Treatment Outcome
chart study
Major depressive disorder
Drug Therapy, Combination
Female
Analysis of variance
Adult
medicine.medical_specialty
augmentation
retrospective
SUICIDE
Randomization
lcsh:RC435-571
Brief Communication
vortioxetine
behavioral disciplines and activities
Statistics, Nonparametric
scale
03 medical and health sciences
Pharmacotherapy
Internal medicine
mental disorders
medicine
Humans
Retrospective Studies
Psychiatric Status Rating Scales
Vortioxetine
Analysis of Variance
Depressive Disorder, Major
business.industry
Reproducibility of Results
Retrospective cohort study
medicine.disease
030227 psychiatry
Clinical Global Impression
business
030217 neurology & neurosurgery
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Brazilian Journal of Psychiatry, Vol 42, Iss 3, Pp 317-321, Brazilian Journal of Psychiatry, Volume: 42, Issue: 3, Pages: 317-321, Published: 09 MAR 2020, Brazilian Journal of Psychiatry, Brazilian Journal of Psychiatry, Issue: ahead, Published: 09 MAR 2020
- Accession number :
- edsair.doi.dedup.....3f46dffe9209c95ad7b031ed4b987dbf